November 03, 2010
Ofirmev approved for management of pain and fever
In a study of 101 orthopedic patients undergoing hip or knee replacement surgery, Ofirmev 1000mg every six hours was statistically superior to placebo for the reduction of pain intensity over 24 hours (p<0.01) with significantly reduced morphine consumption (33% over 24 hours, p<0.01). In a second study of 244 patients undergoing abdominal laparoscopic surgery, Ofirmev 1000mg every six hours, or 650mg every four hours, demonstrated a significant reduction in pain intensity over 24 hours compared to placebo (p<0.02).
In a study of adult volunteers with induced fever, a single dose of Ofirmev 1000mg demonstrated a statistically significant reduction in temperature through six hours in comparison to placebo (p<0.01), with an onset of action within 15 minutes after treatment.
Ofirmev is expected to be available in the first quarter of 2011.
For more information call (877) 647-2239 or visit www.ofirmev.com.